2023
Inflammation, anti-inflammatory agents, and the role of colchicine in carotid artery stenosis.
Chlorogiannis D, Pargaonkar S, Papanagiotou P, Bakogiannis N, Bakoyiannis C, Kokkinidis D. Inflammation, anti-inflammatory agents, and the role of colchicine in carotid artery stenosis. Vasa 2023, 53: 4-12. PMID: 38079179, DOI: 10.1024/0301-1526/a001104.Peer-Reviewed Original ResearchConceptsCarotid artery stenosisArtery stenosisAnti-inflammatory medicationsRole of inflammationCoronary artery diseaseAnti-inflammatory agentsRole of colchicineArtery diseaseOngoing trialsOptimal treatmentCardiovascular diseaseStenosis developmentMedicationsInflammationAvailable evidenceMajor causeStenosisDiseaseColchicineMorbidityPatientsMortalityProgressionTrialsEffects of oral anticoagulation in people with atrial fibrillation after spontaneous intracranial haemorrhage (COCROACH): prospective, individual participant data meta-analysis of randomised trials
Salman R, Stephen J, Tierney J, Lewis S, Newby D, Parry-Jones A, White P, Connolly S, Benavente O, Dowlatshahi D, Cordonnier C, Viscoli C, Sheth K, Kamel H, Veltkamp R, Larsen K, Hofmeijer J, Kerkhoff H, Schreuder F, Shoamanesh A, Klijn C, van der Worp H, Haemorrhage C, Klug D, Casolla B, Puy L, Coffee M, Kuchcinski G, Labreuche J, van Nieuwenhuizen K, Algra A, van Gelder I, Kappelle L, Rinkel G, Schutgens R, Khatri P, Conwit R, Falcone G, Elm J, Anderson C, Song L, Pandian J, Hart R, Sharma M, Aref H, Tarhuni W, Fabregas J, Diener H, Endres M, Lemmens R, Kwon S, Lee B, Ameriso S, Milling T, Kasner S, Mikulik R, Xavier D, Beer R, Toni D, Eckstein J, Seiffge D, Ferro J, Tsivgoulis G, Sharma S, Wei-Liou C, Hohnloser S, Katsanos A, Bosch J, Healey J, Eikelboom J, Khaw A, Gladstone D, Pikula A, Coutts S, Smith E, Butcher K, Field T, Gioia L, Stapf C, Halse O, Ringleb P, Enzinger C, Sibon I, Montaner J, Caso V, Heuschmann P, Lip G, Haefeli W, Debette S, Dennis M, Wyller T, Rønning O, Eilertsen H, Ihle-Hansen H, Sandset E, Pennlert J, Glader E, Kruuse C, Wester P, Carlsson M, Forfang E. Effects of oral anticoagulation in people with atrial fibrillation after spontaneous intracranial haemorrhage (COCROACH): prospective, individual participant data meta-analysis of randomised trials. The Lancet Neurology 2023, 22: 1140-1149. PMID: 37839434, DOI: 10.1016/s1474-4422(23)00315-0.Peer-Reviewed Original ResearchConceptsMajor adverse cardiovascular eventsAdverse cardiovascular eventsSpontaneous intracranial hemorrhageOral anticoagulationCardiovascular eventsIntracranial hemorrhageAtrial fibrillationCardiovascular deathIndividual participant dataEligible trialsHazard ratioPrimary outcomeOngoing trialsFixed-effect inverse variance modelParticipant dataDirect oral anticoagulantsOral anticoagulant agentsCochrane systematic reviewCox regression modelPrevious intracranial hemorrhageInverse variance modelBritish Heart FoundationLong-term useSubgroup of participantsAntiplatelet monotherapyAntiplatelet Strategies Following PCI: A Review of Trials Informing Current and Future Therapies
Thomas A, Gitto M, Shah S, Saito Y, Tirziu D, Chieffo A, Stefanini G, Lansky A. Antiplatelet Strategies Following PCI: A Review of Trials Informing Current and Future Therapies. Journal Of The Society For Cardiovascular Angiography & Interventions 2023, 2: 100607. PMID: 39130709, PMCID: PMC11307978, DOI: 10.1016/j.jscai.2023.100607.Peer-Reviewed Original ResearchDual antiplatelet therapyAntiplatelet regimensPatient-specific risk profileShorter DAPT durationDuration of therapyPercutaneous coronary interventionDAPT strategyIschemic riskAntiplatelet therapyDAPT durationAntiplatelet strategiesCoronary interventionOngoing trialsMajor trialsRecent trialsPractice guidelinesFuture therapiesRisk profileTherapyStent technologyTrialsRegimensNumber of trialsSignificant reductionSignificant changes
2022
Primary prevention statin therapy in older adults
Nanna M, Abdullah A, Mortensen M, Navar A. Primary prevention statin therapy in older adults. Current Opinion In Cardiology 2022, 38: 11-20. PMID: 36598445, PMCID: PMC9830552, DOI: 10.1097/hco.0000000000001003.Peer-Reviewed Original ResearchConceptsAge 75Older adult populationStatin treatmentRandomized trialsAdult populationPrimary prevention statin therapyOlder adultsAverage lifespan increasesRecent guideline recommendationsACC/AHAOngoing randomized trialsPrevention of morbidityPaucity of evidenceStatin therapyStatin useUSPSTF recommendationsOlder patientsGuideline recommendationsOngoing trialsTreatment recommendationsCardiovascular diseaseTreatment benefitTreatment decisionsGuidelines conflictTrialsThe Role of PARP Inhibitors in Patients with Primary Malignant Central Nervous System Tumors
Gueble SE, Vasquez JC, Bindra RS. The Role of PARP Inhibitors in Patients with Primary Malignant Central Nervous System Tumors. Current Treatment Options In Oncology 2022, 23: 1566-1589. PMID: 36242713, DOI: 10.1007/s11864-022-01024-5.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsHomologous recombination deficiencyPrimary CNS tumorsCNS tumorsClinical trialsPARP inhibitorsPreclinical evidencePrimary malignant central nervous system tumorMalignant central nervous system tumorsCentral nervous system tumorsImmune checkpoint inhibitorsStandard treatment modalityInitial clinical trialsEarly phase trialsNervous system tumorsCentral nervous tumorsExtracranial cancerCheckpoint inhibitorsDevastating malignancyStandard therapyOngoing trialsCombination therapyTreatment optionsTreatment modalitiesSystem tumorsPhase trialsGlutamatergic Agents for the Treatment of Cocaine Use Disorder
Hadizadeh H, Flores J, Mayerson T, Worhunsky P, Potenza M, Angarita G. Glutamatergic Agents for the Treatment of Cocaine Use Disorder. Current Behavioral Neuroscience Reports 2022, 9: 101-112. DOI: 10.1007/s40473-022-00252-1.Peer-Reviewed Original ResearchCocaine use disorderRoute of administrationGlutamatergic systemSafety profileNovel agentsUse disordersMetabotropic glutamate receptor 5 antagonistNewer beta-lactam agentsAMPA/kainate receptorsTreatment of CUDBeta-lactam agentsGood safety profileMetabotropic glutamate receptorsPromising preclinical dataReceptors/transportersChronic cocaine useGLT-1 transporterBeta-lactam antibioticsOngoing trialsPreclinical supportGlutamatergic agentsGlutamate neurotransmissionPreclinical dataClinical trialsGlutamate receptorsEVITA Dengue: a cluster-randomized controlled trial to EValuate the efficacy of Wolbachia-InfecTed Aedes aegypti mosquitoes in reducing the incidence of Arboviral infection in Brazil
Collins MH, Potter GE, Hitchings MDT, Butler E, Wiles M, Kennedy JK, Pinto SB, Teixeira ABM, Casanovas-Massana A, Rouphael NG, Deye GA, Simmons CP, Moreira LA, Nogueira ML, Cummings DAT, Ko AI, Teixeira MM, Edupuganti S. EVITA Dengue: a cluster-randomized controlled trial to EValuate the efficacy of Wolbachia-InfecTed Aedes aegypti mosquitoes in reducing the incidence of Arboviral infection in Brazil. Trials 2022, 23: 185. PMID: 35236394, PMCID: PMC8889395, DOI: 10.1186/s13063-022-05997-4.Peer-Reviewed Original ResearchConceptsArboviral infectionsMajor global health problemHigh-quality evidenceCluster-randomized trialGlobal health problemNational InstituteEfficacy of WolbachiaWorld Mosquito ProgramArbovirus transmissionOngoing trialsLicensed antiviralsAedes aegypti mosquitoesEffective vaccineTrial designMosquito ProgramSerologic surveillanceHealth problemsHuman infectionsAedes aegyptiInfectionEpidemiologic outcomesVector control activitiesTrialsAegypti mosquitoesAedes mosquitoesRadiation therapy in the definitive management of medically inoperable endometrial cancer
Chin C, Damast S. Radiation therapy in the definitive management of medically inoperable endometrial cancer. International Journal Of Gynecological Cancer 2022, 32: 323-331. PMID: 35256419, DOI: 10.1136/ijgc-2021-002532.Peer-Reviewed Original ResearchConceptsMultiparametric magnetic resonance imagingInoperable patientsEndometrial cancerImage-guided brachytherapyRadiation therapySystemic anti-tumor immune responseAnti-tumor immune responseThree-dimensional image-guided brachytherapyInoperable endometrial cancerDefinitive radiation therapyPoor surgical candidatesNovel systemic agentsRecent consensus guidelinesHigh-volume centersExtent of tumorRates of obesityMagnetic resonance imagingMedical inoperabilityLate morbiditySurgical candidatesSystemic agentsClinical stagingDefinitive managementOngoing trialsUterine sizeEffect of Exercise on Sarcopenia among Cancer Survivors: A Systematic Review
Cao A, Ferrucci LM, Caan BJ, Irwin ML. Effect of Exercise on Sarcopenia among Cancer Survivors: A Systematic Review. Cancers 2022, 14: 786. PMID: 35159052, PMCID: PMC8833677, DOI: 10.3390/cancers14030786.Peer-Reviewed Original Research
2021
Targeted therapies: Expanding the role of FGFR3 inhibition in urothelial carcinoma
Zengin Z, Chehrazi-Raffle A, Salgia N, Muddasani R, Ali S, Meza L, Pal S. Targeted therapies: Expanding the role of FGFR3 inhibition in urothelial carcinoma. Urologic Oncology Seminars And Original Investigations 2021, 40: 25-36. PMID: 34840077, DOI: 10.1016/j.urolonc.2021.10.003.Peer-Reviewed Original ResearchConceptsImmune checkpoint inhibitorsUrothelial carcinomaCheckpoint inhibitorsTargeted therapyLower tract diseaseMultiple disease stagesMetastatic urothelial carcinomaOverall response rateAntibody-drug conjugatesGrowth factor receptor familyFGFR3 inhibitionUC tumorsChemotherapy regimensUpper tractOngoing trialsDisease stageTract diseaseTreatment paradigmFactor receptor familyHigh incidenceActionable mutationsFGFR1-4FGFR3 inhibitorsSmall molecule inhibitorsFGFR3 mutationsPharmacokinetic (PK) analyses in CSF and plasma from TBCRC049, an ongoing trial to assess the safety and efficacy of the combination of tucatinib, trastuzumab and capecitabine for the treatment of leptomeningeal metastasis (LM) in HER2 positive breast cancer.
Stringer-Reasor E, O'Brien B, Topletz-Erickson A, White J, Lobbous M, Riley K, Childress J, LaMaster K, Melisko M, Morikawa A, De Groot J, Krop I, Valero V, Rimawi M, Wolff A, Tripathy D, Lin N, Murthy R. Pharmacokinetic (PK) analyses in CSF and plasma from TBCRC049, an ongoing trial to assess the safety and efficacy of the combination of tucatinib, trastuzumab and capecitabine for the treatment of leptomeningeal metastasis (LM) in HER2 positive breast cancer. Journal Of Clinical Oncology 2021, 39: 1044-1044. DOI: 10.1200/jco.2021.39.15_suppl.1044.Peer-Reviewed Original ResearchLeptomeningeal metastasesBrain metastasesBreast cancerPharmacokinetic analysisPhase 2 single-arm studyHER2-positive breast cancerCombination of tucatinibNew brain metastasesSingle-arm studyPositive breast cancerTyrosine kinase inhibitorsHigh interindividual variabilityMetastatic HER2Accrual goalEligible patientsMetastatic settingPrimary endpointOverall survivalOmmaya reservoirOngoing trialsPlasma concentrationsCapecitabinePatientsDay 1PK samples
2020
Current and Potential New Targets in Systemic Sclerosis Therapy: a New Hope
Hinchcliff M, O’Reilly S. Current and Potential New Targets in Systemic Sclerosis Therapy: a New Hope. Current Rheumatology Reports 2020, 22: 42. PMID: 32562016, PMCID: PMC7305248, DOI: 10.1007/s11926-020-00918-3.Peer-Reviewed Original ResearchConceptsSkin fibrosisNew targetsSSc interstitial lung diseaseAutoimmune connective tissue diseaseSystemic sclerosis therapyConnective tissue diseaseInterstitial lung diseaseCurrent ongoing trialsNew therapeutic targetsActivation of fibroblastsPotential new targetsReviewSystemic sclerosisSclerosis therapyOngoing trialsTissue diseaseLung diseaseClinical trialsTherapeutic targetRate of declineDisease pathogenesisPhase IIIPhase IIFibrosisNew hopeDiseaseNew Therapies for Hypophosphatemia-Related to FGF23 Excess
Athonvarangkul D, Insogna KL. New Therapies for Hypophosphatemia-Related to FGF23 Excess. Calcified Tissue International 2020, 108: 143-157. PMID: 32504139, DOI: 10.1007/s00223-020-00705-3.BooksConceptsTumor-induced osteomalaciaCutaneous skeletal hypophosphatemia syndromeEpidermal nevus syndromeAutosomal dominant hypophosphatemic ricketsAutosomal recessive hypophosphatemic ricketsHypophosphatemic ricketsForms of FGF23Treatment of XLHActive comparator trialsMainstay of therapyMonoclonal blocking antibodyNew treatment modalitiesMcCune-Albright syndromeRenal phosphate wastingRecessive hypophosphatemic ricketsDominant hypophosphatemic ricketsFGF23 excessComparator trialsSkeletal complicationsChronic hypophosphatemiaMusculoskeletal syndromeOngoing trialsClinical presentationTreatment modalitiesClinical trialsInterrupted Time Series of User‐centered Clinical Decision Support Implementation for Emergency Department–initiated Buprenorphine for Opioid Use Disorder
Holland WC, Nath B, Li F, Maciejewski K, Paek H, Dziura J, Rajeevan H, Lu CC, Katsovich L, D'Onofrio G, Melnick ER. Interrupted Time Series of User‐centered Clinical Decision Support Implementation for Emergency Department–initiated Buprenorphine for Opioid Use Disorder. Academic Emergency Medicine 2020, 27: 753-763. PMID: 32352206, PMCID: PMC7496559, DOI: 10.1111/acem.14002.Peer-Reviewed Original ResearchConceptsOpioid use disorderComputerized clinical decision support systemsRates of EDBUP initiationUse disordersClinical decision support implementationEmergency department initiationRoutine emergency careInterrupted time series studyAdult ED patientsInterrupted time seriesClinical decision support systemElectronic health recordsClinicians' unfamiliarityED initiationDecision support implementationED dischargeOpioid withdrawalSecondary outcomesOngoing trialsPrimary outcomeAcademic EDED patientsSingle EDUnique patientsThe cytoreductive prostatectomy in metastatic prostate cancer: what the individual trials are hoping to answer
Ranasinghe W, Chapin B, Kim I, Sooriakumaran P, Lawrentschuk N. The cytoreductive prostatectomy in metastatic prostate cancer: what the individual trials are hoping to answer. BJU International 2020, 125: 792-800. PMID: 32176456, DOI: 10.1111/bju.15055.Peer-Reviewed Original ResearchConceptsHormone-sensitive metastatic prostate cancerMetastatic prostate cancerCytoreductive prostatectomyAndrogen deprivation therapyProstate cancerOverall survivalRadical prostatectomyLimited bone metastasesCancer-specific outcomesLocal treatment optionsProgression-free survivalDiagnosis of metastasisPrimary outcome measureNovel treatment algorithmOligometastatic settingAdjuvant treatmentMetastatic settingSecondary endpointsCastration resistanceMetastatic diseaseStandard therapyBone metastasesDefinitive treatmentOngoing trialsTreatment algorithm
2019
Beyond Ruxolitinib: Fedratinib and Other Emergent Treatment Options for Myelofibrosis
Bewersdorf JP, Jaszczur SM, Afifi S, Zhao JC, Zeidan AM. Beyond Ruxolitinib: Fedratinib and Other Emergent Treatment Options for Myelofibrosis. Cancer Management And Research 2019, 11: 10777-10790. PMID: 31920387, PMCID: PMC6935287, DOI: 10.2147/cmar.s212559.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsTreatment optionsFavorable risk/benefit ratioRisk/benefit ratioEmergent treatment optionsHigh-risk patientsPhase II trialMain side effectsFuture treatment optionsBone marrow fibrosisGastrointestinal symptomsII trialLiver transaminasesAdverse eventsSymptom burdenOngoing trialsJAK1/2 inhibitorMF patientsMarrow fibrosisClinical trialsSecondary myelofibrosisBox warningSelective JAK2 inhibitorExtramedullary hematopoiesisSecond drugThiamine levelsEPID-23. PURSUIT OF AN INTERNATIONAL LANGUAGE OF GLIOMA RESEARCH: COMMON DATA ELEMENTS FOR THE LONGITUDINAL STUDY OF ADULT MALIGNANT GLIOMA
Poisson L, Kouwenhoven M, Snyder J, Alfaro-Munoz K, Kaur M, Bates A, Verhaak R, Watts C, Zadeh G, Ormond D, Claus E, Khasraw M. EPID-23. PURSUIT OF AN INTERNATIONAL LANGUAGE OF GLIOMA RESEARCH: COMMON DATA ELEMENTS FOR THE LONGITUDINAL STUDY OF ADULT MALIGNANT GLIOMA. Neuro-Oncology 2019, 21: vi79-vi79. PMCID: PMC6847827, DOI: 10.1093/neuonc/noz175.323.Peer-Reviewed Original ResearchAdult malignant gliomasCommon data elementsMalignant gliomasGlioma researchRetrospective chart abstractionLongitudinal studySmall patient populationMulti-center collaborationResearch Electronic Data Capture (REDCap) systemChart abstractionPatient demographicsClinical courseClinical featuresOngoing trialsClinical variablesPatient populationUncommon cancerMedical historyClinical dataTranslational studiesGlioma Longitudinal Analysis ConsortiumClinical standardsMultidisciplinary expertsConfirmatory studiesGliomas1198P FPA150 (B7-H4 antibody) phase I update in advanced solid tumours: Monotherapy and in combination with pembrolizumab
Wainberg Z, Sachdev J, Bauer T, Pant S, Chawla S, Marina N, Xiang H, Deng W, Schmidt M, Patnaik A, LoRusso P. 1198P FPA150 (B7-H4 antibody) phase I update in advanced solid tumours: Monotherapy and in combination with pembrolizumab. Annals Of Oncology 2019, 30: v489. DOI: 10.1093/annonc/mdz253.024.Peer-Reviewed Original ResearchTreatment-related adverse eventsAdvanced solid tumorsB7-H4Prime TherapeuticsSolid tumorsAdverse eventsEli LillyTreatment-related serious adverse eventsAntibody-dependent cell-mediated cytotoxicityAnti-PD1 agentsB7-H4 antibodyDose-proportional exposureSerious adverse eventsDose-limiting toxicityCell-mediated cytotoxicityCommon being diarrheaGlaxo Smith KlineBristol-Myers SquibbDrug discontinuationGuardant HealthKaryopharm TherapeuticsSarcoma AllianceDose expansionDose escalationOngoing trialsSurvival rates after retroperitoneal lymph node dissection (RPLND) for testicular seminoma.
Tabakin A, Kim S, Polotti C, Shinder B, Rivera-Nunez Z, Sterling J, Farber N, Radadia K, Kim I, Singer E, Jang T. Survival rates after retroperitoneal lymph node dissection (RPLND) for testicular seminoma. Journal Of Clinical Oncology 2019, 37: 534-534. DOI: 10.1200/jco.2019.37.7_suppl.534.Peer-Reviewed Original ResearchRetroperitoneal lymph node dissectionOverall survival rateTesticular seminomaSurvival rateOverall survivalClinical stagePC settingsUnderwent retroperitoneal lymph node dissectionComprehensive community cancer programsFive-year overall survivalNational Cancer DatabaseCommunity cancer programsFirst-line treatmentLow-volume diseaseLymph node dissectionKaplan-Meier methodSurvival dataAvailable survival dataMajority of menNonseminoma histologyPrior chemotherapyNode dissectionSeminoma patientsFinal cohortOngoing trials
2017
Olaratumab for the treatment of soft tissue sarcoma.
Deshpande HA, Cecchini M, Ni Choileain S, Jones R. Olaratumab for the treatment of soft tissue sarcoma. Drugs Of Today 2017, 53: 247-255. PMID: 28492292, DOI: 10.1358/dot.2017.53.4.2560077.Peer-Reviewed Original ResearchConceptsSoft tissue sarcomasPhase II studyTissue sarcomasII studyMetastatic diseaseOverall survivalOngoing phase III studiesRandomized phase II studyPlatelet-derived growth factor receptor alphaProgression-free survivalPhase III studyStandard chemotherapy regimensGrowth factor receptor alphaUnited States FoodMechanism of actionChemotherapy regimensIII studyOngoing trialsSolid malignanciesReceptor alphaPhase IbDrug AdministrationSignificant improvementFDA approvalOlaratumab
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply